Geneva, Aug. 31 -- International Clinical Trials Registry received information related to the study (NCT07780110) titled 'Compassionate Use of Vonsetamig' on Aug. 18.
Study Type: Expanded Access
Primary Sponsor: Regeneron Pharmaceuticals
Condition:
Plasma Cell Mediated
Antibody Mediated
Intervention:
Drug: Vonsetamig
Recruitment Status: Not recruiting
Date of First Enrollment: August 12, 2026
To know more, visit https://clinicaltrials.gov/study/NCT07780110
Disclaimer: Curated by HT Syndication....